Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study

David T Yeung, On Behalf of the ALLG, Naranie Shanmuganathan et al.|Blood|2019

Cited by 3